New Two-Pronged cancer shot tested in patients out of options
NCT ID NCT05322408
Summary
This early-stage study tested a new injectable drug called HCW9218 in 18 people with advanced solid tumors that had stopped responding to at least two prior treatments. The main goal was to find the highest safe dose. The drug is designed to work like a double agent: it aims to both block a protein that helps tumors hide from the immune system and activate immune cells to attack the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Masonic Cancer Center - University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.